{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:18:35Z","timestamp":1740143915308,"version":"3.37.3"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T00:00:00Z","timestamp":1701993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T00:00:00Z","timestamp":1701993600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s11523-023-01017-w","type":"journal-article","created":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T10:01:58Z","timestamp":1702029718000},"page":"13-28","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Malignant Pleural Mesothelioma: Staging and Radiological Response Criteria in Patients Treated with Immune Checkpoint Inhibitors"],"prefix":"10.1007","volume":"19","author":[{"given":"Serafina","family":"Martella","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco Maria","family":"Aiello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Bertaglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo","family":"Cau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nerina","family":"Denaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Cadoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Novello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Scartozzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Novello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hector Jos\u00e8","family":"Soto Parra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Saba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cinzia","family":"Solinas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3090-8541","authenticated-orcid":false,"given":"Michele","family":"Porcu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,12,8]]},"reference":[{"key":"1017_CR1","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1200\/JCO.2017.76.6394","volume":"36","author":"HL Kindler","year":"2018","unstructured":"Kindler HL, Ismaila N, Armato SG 3rd, Bueno R, Hesdorffer M, Jahan T, et al. Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018;36:1343\u201373. https:\/\/doi.org\/10.1200\/JCO.2017.76.6394.","journal-title":"J Clin Oncol"},{"key":"1017_CR2","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1136\/thorax.58.9.809","volume":"58","author":"C Parker","year":"2003","unstructured":"Parker C, Neville E. Lung cancer * 8: management of malignant mesothelioma. Thorax. 2003;58:809\u201313. https:\/\/doi.org\/10.1136\/thorax.58.9.809.","journal-title":"Thorax"},{"key":"1017_CR3","unstructured":"WHO Classification of Tumours Editorial Board. Thoracic Tumours. Chapter 2: Tumours of the pleura and pericardium. IARC, Lyon; 2021."},{"key":"1017_CR4","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1038\/bjc.2013.514","volume":"109","author":"G Frost","year":"2013","unstructured":"Frost G. The latency period of mesothelioma among a cohort of British asbestos workers (1978\u20132005). Br J Cancer. 2013;109:1965\u201373. https:\/\/doi.org\/10.1038\/bjc.2013.514.","journal-title":"Br J Cancer"},{"key":"1017_CR5","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s00420-019-01433-4","volume":"92","author":"P Boffetta","year":"2019","unstructured":"Boffetta P, Donato F, Pira E, Luu HN, La Vecchia C. Risk of mesothelioma after cessation of asbestos exposure: A systematic review and meta-regression. Int Arch Occup Environ Health. 2019;92:949\u201357. https:\/\/doi.org\/10.1007\/s00420-019-01433-4.","journal-title":"Int Arch Occup Environ Health"},{"key":"1017_CR6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.critrevonc.2016.05.004","volume":"104","author":"S Novello","year":"2016","unstructured":"Novello S, Pinto C, Torri V, Porcu L, Di Maio M, Tiseo M, et al. The Third Italian Consensus Conference for Malignant Pleural Mesothelioma: State of the art and recommendations. Crit Rev Oncol Hematol. 2016;104:9\u201320. https:\/\/doi.org\/10.1016\/j.critrevonc.2016.05.004.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"Suppl 1","key":"1017_CR7","doi-asserted-by":"publisher","first-page":"i1","DOI":"10.1136\/thoraxjnl-2017-211321","volume":"73","author":"I Woolhouse","year":"2018","unstructured":"Woolhouse I, Bishop L, Darlison L, De Fonseka D, Edey A, Edwards J, et al. British Thoracic Society guideline for the investigation and management of malignant pleural mesothelioma. Thorax. 2018;73(Suppl 1):i1\u201330. https:\/\/doi.org\/10.1136\/thoraxjnl-2017-211321.","journal-title":"Thorax"},{"key":"1017_CR8","doi-asserted-by":"publisher","first-page":"543","DOI":"10.21037\/tlcr.2018.07.05","volume":"7","author":"L Berzenji","year":"2018","unstructured":"Berzenji L, Van Schil PE, Carp L. The eighth TNM classification for malignant pleural mesothelioma. Transl Lung Cancer Res. 2018;7:543\u20139. https:\/\/doi.org\/10.21037\/tlcr.2018.07.05.","journal-title":"Transl Lung Cancer Res."},{"issue":"6","key":"1017_CR9","doi-asserted-by":"publisher","first-page":"E254","DOI":"10.3978\/j.issn.2072-1439.2013.11.28","volume":"5","author":"N Van Zandwijk","year":"2013","unstructured":"Van Zandwijk N, Clarke C, Henderson D, Musk AW, Fong K, Nowak A, et al. Guidelines for the diagnosis and treatment of malignant pleural mesothelioma. J Thorac Dis. 2013;5(6):E254-307. https:\/\/doi.org\/10.3978\/j.issn.2072-1439.2013.11.28.","journal-title":"J Thorac Dis"},{"issue":"5 suppl","key":"1017_CR10","doi-asserted-by":"publisher","first-page":"v31","DOI":"10.1093\/annonc\/mdv199","volume":"26","author":"P Baas","year":"2015","unstructured":"Baas P, Fennell D, Kerr KM, Van Schil PE, Haas RL, Peters S, et al. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(5 suppl):v31\u20139. https:\/\/doi.org\/10.1093\/annonc\/mdv199.","journal-title":"Ann Oncol"},{"issue":"14","key":"1017_CR11","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636\u201344. https:\/\/doi.org\/10.1200\/JCO.2003.11.136.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1017_CR12","doi-asserted-by":"publisher","first-page":"402","DOI":"10.3322\/caac.21572","volume":"69","author":"M Carbone","year":"2019","unstructured":"Carbone M, Adusumilli PS, Alexander HR Jr, Baas P, Bardelli F, Bononi A, et al. Mesothelioma: Scientific clues for prevention, diagnosis, and therapy. CA Cancer J Clin. 2019;69(5):402\u201329. https:\/\/doi.org\/10.3322\/caac.21572.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"1017_CR13","doi-asserted-by":"publisher","first-page":"89","DOI":"10.5858\/arpa.2017-0124-RA","volume":"142","author":"AN Husain","year":"2017","unstructured":"Husain AN, Colby T, Ordonez N, Allen TC, Attanoos RL, Beasley MB, et al. Guidelines for pathologic diagnosis of malignant mesothelioma: 2017 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med. 2017;142(1):89\u2013108. https:\/\/doi.org\/10.5858\/arpa.2017-0124-RA.","journal-title":"Arch Pathol Lab Med"},{"issue":"3","key":"1017_CR14","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.lungcan.2015.08.012","volume":"90","author":"L Cheng","year":"2015","unstructured":"Cheng L, Tunariu N, Collins DJ, Blackledge MD, Riddell AM, Leach MO, et al. Response evaluation in mesothelioma: beyond RECIST. Lung Cancer. 2015;90(3):433\u201341. https:\/\/doi.org\/10.1016\/j.lungcan.2015.08.012.","journal-title":"Lung Cancer"},{"issue":"10","key":"1017_CR15","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1016\/j.jtho.2019.08.012","volume":"14","author":"RR Gill","year":"2019","unstructured":"Gill RR, Tsao AS, Kindler HL, Richards WG, Armato SG 3rd, Francis RJ, et al. Radiologic considerations and standardization of malignant pleural mesothelioma imaging within clinical trials: consensus statement from the NCI Thoracic Malignancy Steering Committee \u2013 International Association for the Study of Lung Cancer \u2013 Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting. J Thorac Oncol. 2019;14(10):1718\u201331. https:\/\/doi.org\/10.1016\/j.jtho.2019.08.012.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"1017_CR16","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1186\/s12885-019-6419-1","volume":"19","author":"T Kishimoto","year":"2019","unstructured":"Kishimoto T, Fujimoto N, Ebara T, Omori T, Oguri T, Niimi A, et al. Serum levels of the chemokine CCL2 are elevated in malignant pleural mesothelioma patients. BMC Cancer. 2019;19(1):1204. https:\/\/doi.org\/10.1186\/s12885-019-6419-1.","journal-title":"BMC Cancer"},{"key":"1017_CR17","doi-asserted-by":"publisher","first-page":"4388","DOI":"10.1158\/0008-5472.CAN-14-1328","volume":"74","author":"J Xu","year":"2014","unstructured":"Xu J, Kadariya Y, Cheung M, Pei J, Talarchek J, Sementino E, et al. Germline mutation of Bap1 accelerates development of asbestos-induced malignant mesothelioma. Cancer Res. 2014;74:4388\u201397. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-1328.","journal-title":"Cancer Res"},{"key":"1017_CR18","doi-asserted-by":"publisher","first-page":"4327","DOI":"10.3390\/ijms21124327","volume":"21","author":"V Panou","year":"2020","unstructured":"Panou V, R\u00f8e OD. Inherited genetic mutations and polymorphisms in malignant mesothelioma: a comprehensive review. Int J Mol Sci. 2020;21:4327. https:\/\/doi.org\/10.3390\/ijms21124327.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"1017_CR19","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1148\/rg.346130089","volume":"34","author":"LT Nickell Jr","year":"2014","unstructured":"Nickell LT Jr, Lichtenberger JP 3rd, Khorashadi L, Abbott GF, Carter BW. Multimodality imaging for characterization, classification, and staging of malignant pleural mesothelioma. Radiographics. 2014;34(6):1692\u2013706. https:\/\/doi.org\/10.1148\/rg.346130089.","journal-title":"Radiographics"},{"issue":"7","key":"1017_CR20","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.jtho.2018.04.034","volume":"13","author":"SG Armato 3rd","year":"2018","unstructured":"Armato SG 3rd, Nowak AK. Revised modified response evaluation criteria in solid tumors for assessment of response in malignant pleural mesothelioma (Version 1.1). J Thorac Oncol. 2018;13(7):1012\u201321. https:\/\/doi.org\/10.1016\/j.jtho.2018.04.034.","journal-title":"J Thorac Oncol"},{"issue":"5","key":"1017_CR21","doi-asserted-by":"publisher","first-page":"543","DOI":"10.21037\/tlcr.2018.07.05","volume":"7","author":"L Berzenji","year":"2018","unstructured":"Berzenji L, Van Schil PE, Carp L. The eighth TNM classification for malignant pleural mesothelioma. Transl Lung Cancer Res. 2018;7(5):543\u20139. https:\/\/doi.org\/10.21037\/tlcr.2018.07.05.","journal-title":"Transl Lung Cancer Res."},{"issue":"12","key":"1017_CR22","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1016\/j.jtho.2016.09.123","volume":"11","author":"H Pass","year":"2016","unstructured":"Pass H, Giroux D, Kennedy C, Ruffini E, Cangir AK, Rice D, et al. The IASLC mesothelioma staging project: improving staging of a rare disease through international participation. J Thorac Oncol. 2016;11(12):2082\u20138. https:\/\/doi.org\/10.1016\/j.jtho.2016.09.123.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"1017_CR23","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3322\/caac.21388","volume":"67","author":"MB Amin","year":"2017","unstructured":"Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The Eighth edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging. CA Cancer J Clin. 2017;67(2):93\u20139. https:\/\/doi.org\/10.3322\/caac.21388.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"1017_CR24","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1200\/OP.21.00426","volume":"18","author":"AK Nowak","year":"2022","unstructured":"Nowak AK, Jackson A, Sidhu C. Management of advanced pleural mesothelioma\u2014at the crossroads. JCO Oncol Pract. 2022;18(2):116\u201324. https:\/\/doi.org\/10.1200\/OP.21.00426.","journal-title":"JCO Oncol Pract."},{"issue":"6","key":"1017_CR25","doi-asserted-by":"publisher","first-page":"1900953","DOI":"10.1183\/13993003.00953-2019","volume":"55","author":"A Scherpereel","year":"2020","unstructured":"Scherpereel A, Opitz I, Berghmans T, Psallidas I, Glatzer M, Rigau D, et al. ERS\/ESTS\/EACTS\/ESTRO guidelines for the management of malignant pleural mesothelioma. Eur Respir J. 2020;55(6):1900953. https:\/\/doi.org\/10.1183\/13993003.00953-2019.","journal-title":"Eur Respir J"},{"issue":"5","key":"1017_CR26","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1007\/s12094-020-02532-2","volume":"23","author":"E Nadal","year":"2021","unstructured":"Nadal E, Bosch-Barrera J, Cedr\u00e9s S, et al. SEOM clinical guidelines for the treatment of malignant pleural mesothelioma (2020). Clin Transl Oncol. 2021;23(5):980\u20137. https:\/\/doi.org\/10.1007\/s12094-020-02532-2.","journal-title":"Clin Transl Oncol"},{"issue":"6","key":"1017_CR27","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.crad.2019.12.001","volume":"75","author":"S Sinha","year":"2020","unstructured":"Sinha S, Swift AJ, Kamil MA, Matthews S, Bull MJ, Fisher P, et al. The role of imaging in malignant pleural mesothelioma: an update after the 2018 BTS guidelines. Clin Radiol. 2020;75(6):423\u201332. https:\/\/doi.org\/10.1016\/j.crad.2019.12.001.","journal-title":"Clin Radiol"},{"issue":"1","key":"1017_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2017-000266","volume":"5","author":"I Woolhouse","year":"2018","unstructured":"Woolhouse I, Bishop L, Darlison L, de Fonseka D, Edey A, Edwards J, Faivre-Finn C, et al. BTS guideline for the investigation and management of malignant pleural mesothelioma. BMJ Open Respir Res. 2018;5(1): e000266. https:\/\/doi.org\/10.1136\/bmjresp-2017-000266.","journal-title":"BMJ Open Respir Res"},{"issue":"12","key":"1017_CR29","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1016\/j.jtho.2016.08.147","volume":"11","author":"AK Nowak","year":"2016","unstructured":"Nowak AK, Chansky K, Rice DC, Pass HI, Kindler HL, Shemanski L, Bill\u00e9 A, et al. The IASLC Mesothelioma Staging Project: proposals for revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for pleural mesothelioma. J Thorac Oncol. 2016;11(12):2089\u201399. https:\/\/doi.org\/10.1016\/j.jtho.2016.08.147.","journal-title":"J Thorac Oncol"},{"issue":"17","key":"1017_CR30","doi-asserted-by":"publisher","first-page":"4377","DOI":"10.3390\/cancers13174377","volume":"13","author":"C Romei","year":"2021","unstructured":"Romei C, Fanni SC, Volpi F, Milazzo A, D\u2019Amore CA, Colligiani L, et al. New updates of the imaging role in diagnosis, staging, and response treatment of malignant pleural mesothelioma. Cancers (Basel). 2021;13(17):4377. https:\/\/doi.org\/10.3390\/cancers13174377.","journal-title":"Cancers (Basel)."},{"issue":"10","key":"1017_CR31","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1097\/RLI.0b013e3181817b3d","volume":"43","author":"C Plathow","year":"2008","unstructured":"Plathow C, Staab A, Schmaehl A, Aschoff P, Zuna I, Pfannenberg C, Peter SH, et al. Computed tomography, positron emission tomography, positron emission tomography\/computed tomography, and magnetic resonance imaging for staging of limited pleural mesothelioma: initial results. Invest Radiol. 2008;43(10):737\u201344. https:\/\/doi.org\/10.1097\/RLI.0b013e3181817b3d.","journal-title":"Invest Radiol"},{"key":"1017_CR32","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.lungcan.2018.01.014","volume":"118","author":"S Tsim","year":"2018","unstructured":"Tsim S, Humphreys CA, Cowell GW, Stobo DB, Noble C, Woodward R, Kelly CA, Alexander L, Foster JE, Dick C, Blyth KG. Early Contrast Enhancement: a novel magnetic resonance imaging biomarker of pleural malignancy. Lung Cancer. 2018;118:48\u201356. https:\/\/doi.org\/10.1016\/j.lungcan.2018.01.014.","journal-title":"Lung Cancer"},{"issue":"1086","key":"1017_CR33","doi-asserted-by":"publisher","first-page":"20170814","DOI":"10.1259\/bjr.20170814E","volume":"91","author":"HS Elliott","year":"2018","unstructured":"Elliott HS, Metser U, de Perrot M, Cho J, Bradbury P, Veit-Haibach P, et al. 18F-FDG PET\/CT in the management of patients with malignant pleural mesothelioma being considered for multimodality therapy: experience of a tertiary referral center. Br J Radiol. 2018;91(1086):20170814. https:\/\/doi.org\/10.1259\/bjr.20170814E.","journal-title":"Br J Radiol"},{"issue":"Suppl 2","key":"1017_CR34","doi-asserted-by":"publisher","first-page":"S253","DOI":"10.21037\/jtd.2017.10.09","volume":"10","author":"A Bianco","year":"2018","unstructured":"Bianco A, Valente T, De Rimini ML, Sica G, Fiorelli A. Clinical diagnosis of malignant pleural mesothelioma. J Thorac Dis. 2018;10(Suppl 2):S253\u201361. https:\/\/doi.org\/10.21037\/jtd.2017.10.09.","journal-title":"J Thorac Dis"},{"key":"1017_CR35","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.critrevonc.2017.09.017","volume":"120","author":"C Solinas","year":"2017","unstructured":"Solinas C, Porcu M, Hlavata Z, De Silva P, Puzzoni M, Willard-Gallo K, Scartozzi M, Saba L. Critical features and challenges associated with imaging in patients undergoing cancer immunotherapy. Crit Rev Oncol Hematol. 2017;120:13\u201321. https:\/\/doi.org\/10.1016\/j.critrevonc.2017.09.017.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"1017_CR36","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer"},{"issue":"3","key":"1017_CR37","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","volume":"18","author":"L Seymour","year":"2017","unstructured":"Seymour L, Bogaerts J, Perrone A, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18(3):e143\u201352. https:\/\/doi.org\/10.1016\/S1470-2045(17)30074-8.","journal-title":"Lancet Oncol"},{"issue":"13","key":"1017_CR38","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/s0959-8049(99)00229-4","volume":"35","author":"H Young","year":"1999","unstructured":"Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 1999;35(13):1773\u201382. https:\/\/doi.org\/10.1016\/s0959-8049(99)00229-4.","journal-title":"Eur J Cancer"},{"issue":"Suppl 1","key":"1017_CR39","doi-asserted-by":"publisher","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","volume":"50","author":"RL Wahl","year":"2009","unstructured":"Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl 1):122S-S150. https:\/\/doi.org\/10.2967\/jnumed.108.057307.","journal-title":"J Nucl Med"},{"issue":"1","key":"1017_CR40","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.cllc.2019.08.003","volume":"21","author":"H Doi","year":"2020","unstructured":"Doi H, Kuribayashi K, Kitajima K, Yamakado K, Kijima T. Development of a novel prognostic risk classification system for malignant pleural mesothelioma. Clin Lung Cancer. 2020;21(1):66\u201374. https:\/\/doi.org\/10.1016\/j.cllc.2019.08.003. (e2).","journal-title":"Clin Lung Cancer"},{"key":"1017_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.103068","volume":"154","author":"M Porcu","year":"2020","unstructured":"Porcu M, Solinas C, Mannelli L, et al. Radiomics and \u201cradi-\u2026omics\u201d in cancer immunotherapy: a guide for clinicians. Crit Rev Oncol Hematol. 2020;154: 103068. https:\/\/doi.org\/10.1016\/j.critrevonc.2020.103068.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"6","key":"1017_CR42","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1378\/chest.129.6.1570","volume":"129","author":"FL Giesel","year":"2006","unstructured":"Giesel FL, Bischoff H, von Tengg-Kobligk H, Weber MA, Zechmann CM, Kauczor HU, et al. Dynamic contrast-enhanced MRI of malignant pleural mesothelioma: a feasibility study of noninvasive assessment, therapeutic follow-up, and possible predictor of improved outcome. Chest. 2006;129(6):1570\u20136. https:\/\/doi.org\/10.1378\/chest.129.6.1570.","journal-title":"Chest"},{"issue":"1","key":"1017_CR43","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s12885-022-09277-x","volume":"22","author":"M Vivoda Tom\u0161i\u010d","year":"2022","unstructured":"Vivoda Tom\u0161i\u010d M, Koro\u0161ec P, Kova\u010d V, Bisdas S, \u0160urlan PK. Dynamic contrast-enhanced MRI in malignant pleural mesothelioma: prediction of outcome based on DCE-MRI measurements in patients undergoing cytotoxic chemotherapy. BMC Cancer. 2022;22(1):191. https:\/\/doi.org\/10.1186\/s12885-022-09277-x.","journal-title":"BMC Cancer"},{"issue":"3","key":"1017_CR44","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1148\/radiol.2018182768","volume":"290","author":"KS Lee","year":"2019","unstructured":"Lee KS, Lee HY. Does spectral CT provide added diagnostic value for defining malignant pleural disease? Radiology. 2019;290(3):805\u20136. https:\/\/doi.org\/10.1148\/radiol.2018182768.","journal-title":"Radiology"},{"issue":"7","key":"1017_CR45","doi-asserted-by":"publisher","first-page":"838","DOI":"10.3348\/kjr.2019.0711","volume":"21","author":"C Kim","year":"2020","unstructured":"Kim C, Kim W, Park SJ, Hwang SH, Yong HS, Oh YW, et al. Application of dual-energy spectral computed tomography to thoracic oncology imaging. Korean J Radiol. 2020;21(7):838\u201350. https:\/\/doi.org\/10.3348\/kjr.2019.0711.","journal-title":"Korean J Radiol"},{"issue":"1","key":"1017_CR46","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13550-020-00669-3","volume":"10","author":"M Pavic","year":"2020","unstructured":"Pavic M, Bogowicz M, Kraft J, Vuong D, Mayinger M, Kroeze SGC, et al. FDG PET versus CT radiomics to predict outcome in malignant pleural mesothelioma patients. EJNMMI Res. 2020;10(1):81. https:\/\/doi.org\/10.1186\/s13550-020-00669-3.","journal-title":"EJNMMI Res"},{"issue":"5","key":"1017_CR47","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1053\/j.seminoncol.2010.09.006","volume":"37","author":"L Calabr\u00f2","year":"2010","unstructured":"Calabr\u00f2 L, Danielli R, Sigalotti L, Maio M, et al. Clinical studies with anti-CTLA-4 antibodies in non-melanoma indications. Semin Oncol. 2010;37(5):460\u20137.","journal-title":"Semin Oncol"},{"issue":"10","key":"1017_CR48","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1200\/JCO.2014.56.6018","volume":"33","author":"M Maio","year":"2015","unstructured":"Maio M, Grob JJ, Aamdal S, Bondarenko I, Robert C, Thomas L, Garbe C, et al. Five-year survival rates for treatment-I patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J Clin Oncol. 2015;33(10):1191\u20136.","journal-title":"J Clin Oncol"},{"key":"1017_CR49","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","volume":"397","author":"P Baas","year":"2021","unstructured":"Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomized, open-label, phase 3 trial. Lancet. 2021;397:375\u201386.","journal-title":"Lancet"},{"issue":"5","key":"1017_CR50","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.annonc.2022.01.074","volume":"33","author":"S Peters","year":"2022","unstructured":"Peters S, Scherpereel A, Cornelissen R, et al. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Ann Oncol. 2022;33(5):488\u201399. https:\/\/doi.org\/10.1016\/j.annonc.2022.01.074.","journal-title":"Ann Oncol"},{"issue":"6","key":"1017_CR51","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S2213-2600(18)30151-6","volume":"6","author":"L Calabr\u00f2","year":"2018","unstructured":"Calabr\u00f2 L, Morra A, Giannarelli D, et al. Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study. Lancet Respir Med. 2018;6(6):451\u201360. https:\/\/doi.org\/10.1016\/S2213-2600(18)30151-6.","journal-title":"Lancet Respir Med"},{"issue":"3","key":"1017_CR52","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/S2213-2600(18)30420-X","volume":"7","author":"MJ Disselhorst","year":"2019","unstructured":"Disselhorst MJ, Quispel-Janssen J, Lalezari F, et al. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial. Lancet Respir Med. 2019;7(3):260\u201370. https:\/\/doi.org\/10.1016\/S2213-2600(18)30420-X.","journal-title":"Lancet Respir Med"},{"issue":"2","key":"1017_CR53","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","volume":"20","author":"A Scherpereel","year":"2019","unstructured":"Scherpereel A, Mazieres J, Greillier L, et al. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. Lancet Oncol. 2019;20(2):239\u201353. https:\/\/doi.org\/10.1016\/S1470-2045(18)30765-4.","journal-title":"Lancet Oncol"},{"key":"1017_CR54","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","volume":"18","author":"EW Alley","year":"2017","unstructured":"Alley EW, Lopez J, Santoro A, Morosky A, Saraf S, Piperdi B, et al. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2017;18:623\u201330.","journal-title":"Lancet Oncol"},{"key":"1017_CR55","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S2213-2600(20)30515-4","volume":"9","author":"TA Yap","year":"2021","unstructured":"Yap TA, Nakagawa K, Fujimoto N, Kuribayashi K, Guren TK, Calabr\u00f2 L, et al. Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study. Lancet Respir Med. 2021;9:613\u201321.","journal-title":"Lancet Respir Med"},{"issue":"10","key":"1017_CR56","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/j.jtho.2018.05.038","volume":"13","author":"J Quispel-Janssen","year":"2018","unstructured":"Quispel-Janssen J, van der Noort V, de Vries JF, et al. Programmed death 1 blockade with nivolumab in patients with recurrent malignant pleural mesothelioma. J Thorac Oncol. 2018;13(10):1569\u201376. https:\/\/doi.org\/10.1016\/j.jtho.2018.05.038.","journal-title":"J Thorac Oncol"},{"issue":"18","key":"1017_CR57","doi-asserted-by":"publisher","first-page":"5485","DOI":"10.1158\/1078-0432.CCR-19-0103","volume":"25","author":"M Okada","year":"2019","unstructured":"Okada M, Kijima T, Aoe K, et al. Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT). Clin Cancer Res. 2019;25(18):5485\u201392. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-0103.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"1017_CR58","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1016\/S1470-2045(21)00471-X","volume":"22","author":"DA Fennell","year":"2021","unstructured":"Fennell DA, Ewings S, Ottensmeier C, et al. Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial. Lancet Oncol. 2021;22(11):1530\u201340. https:\/\/doi.org\/10.1016\/S1470-2045(21)00471-X.","journal-title":"Lancet Oncol"},{"issue":"3","key":"1017_CR59","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1001\/jamaoncol.2018.5428","volume":"5","author":"R Hassan","year":"2019","unstructured":"Hassan R, Thomas A, Nemunaitis JJ, et al. Efficacy and safety of avelumab treatment in patients with advanced unresectable mesothelioma: phase 1b results from the JAVELIN solid tumor trial. JAMA Oncol. 2019;5(3):351\u20137. https:\/\/doi.org\/10.1001\/jamaoncol.2018.5428.","journal-title":"JAMA Oncol"},{"key":"1017_CR60","unstructured":"National Comprehensive Cancer Network. Malignant Pleural Mesothelioma. Version 2. 2021. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/mpm.pdf."},{"key":"1017_CR61","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1158\/1078-0432.CCR-17-3757","volume":"24","author":"S Khanna","year":"2018","unstructured":"Khanna S, Graef S, Mussai F, Thomas A, Wali N, Yenidunya BG, et al. Tumor-derived GM-CSF promotes granulocyte immunosuppression in mesothelioma patients. Clin Cancer Res. 2018;24:2859\u201372.","journal-title":"Clin Cancer Res"},{"key":"1017_CR62","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/s41379-019-0364-z","volume":"33","author":"S Muller","year":"2020","unstructured":"Muller S, Lai WV, Adusumilli PS, Desmeules P, Frosina D, Jungbluth A, et al. V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma. Mod Pathol. 2020;33:303\u201311.","journal-title":"Mod Pathol"},{"key":"1017_CR63","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/s41379-019-0328-3","volume":"33","author":"YS Chung","year":"2020","unstructured":"Chung YS, Kim M, Cha YJ, Kim KA, Shim HS, et al. Expression of V-set immunoregulatory receptor in malignant mesothelioma. Mod Pathol. 2020;33:263\u201370.","journal-title":"Mod Pathol"},{"key":"1017_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2020.188386","volume":"1874","author":"T Van den Ende","year":"2020","unstructured":"Van den Ende T, van den Boorn HG, Hoonhout NM, van Etten-Jamaludin FS, Meijer SL, Derks S, et al. Priming the tumor immune microenvironment with chemo(radio)therapy: a systematic review across tumor types. Biochim Biophys Acta Rev Cancer. 2020;1874: 188386.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"1017_CR65","doi-asserted-by":"publisher","first-page":"6345","DOI":"10.1158\/1078-0432.CCR-18-1231","volume":"24","author":"PT De Lara","year":"2018","unstructured":"De Lara PT, Cecconi V, Hiltbrunner S, Yagita H, Friess M, Bode B, et al. Gemcitabine synergizes with immune checkpoint inhibitors and overcomes resistance in a preclinical model and mesothelioma patients. Clin Cancer Res. 2018;24:6345\u201354.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1017_CR66","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.trecan.2020.01.005","volume":"6","author":"JJ Adashek","year":"2020","unstructured":"Adashek JJ, Subbiah IM, Matos I, Garralda E, Menta AK, Ganeshan DM, et al. Hyperprogression and immunotherapy: fact, fiction, or alternative fact? Trends Cancer. 2020;6(3):181\u201391.","journal-title":"Trends Cancer"},{"key":"1017_CR67","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1001\/jamaoncol.2018.3676","volume":"4","author":"R Ferrara","year":"2018","unstructured":"Ferrara R, Mezquita L, Texier M, Lahmar J, Audigier-Valette C, Tessonnier L, et al. Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1\/PD-L1 inhibitors or with single-agent chemotherapy. JAMA Oncol. 2018;4:1543\u201352.","journal-title":"JAMA Oncol"},{"key":"1017_CR68","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1016\/j.jtho.2019.05.033","volume":"14","author":"Y Kim","year":"2019","unstructured":"Kim Y, Kim CH, Lee HY, Lee SH, Kim HS, Lee S, et al. Comprehensive clinical and genetic characterization of hyperprogression based on volumetry in advanced non-small cell lung cancer treated with immune checkpoint inhibitor. J Thorac Oncol. 2019;14:1608\u201318.","journal-title":"J Thorac Oncol"},{"key":"1017_CR69","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1158\/1078-0432.CCR-19-2226","volume":"26","author":"I Matos","year":"2020","unstructured":"Matos I, Martin-Liberal J, Garc\u00eda-Ruiz A, Hierro C, Ochoa de Olza M, et al. Capturing hyperprogressive disease with immune-checkpoint inhibitors using RECIST 1.1 Criteria. Clin Cancer Res. 2020;26:1846\u201355.","journal-title":"Clin Cancer Res"},{"key":"1017_CR70","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","volume":"20","author":"A Scherpereel","year":"2019","unstructured":"Scherpereel A, Mazieres J, Greillier L, Lantuejoul S, D\u00f4 P, Bylicki O, et al. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, andomized, non-comparative, phase 2 trial. Lancet Oncol. 2019;20:239\u201353.","journal-title":"Lancet Oncol"},{"key":"1017_CR71","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1093\/annonc\/mdx178","volume":"28","author":"E Sa\u00e2da-Bouzid","year":"2017","unstructured":"Sa\u00e2da-Bouzid E, Defaucheux C, Karabajakian A, Coloma VP, Servois V, Paoletti X, et al. Hyperprogression during anti-PD-1\/PD-L1 therapy in patients with recurrent and\/or metastatic head and neck squamous cell carcinoma. Ann Oncol. 2017;28:1605\u201311.","journal-title":"Ann Oncol"},{"issue":"6","key":"1017_CR72","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.21037\/tlcr-20-636","volume":"10","author":"R Ferrara","year":"2021","unstructured":"Ferrara R, Signorelli D, Proto C, Prelaj A, Garassino MC, Lo RG, et al. Novel patterns of progression upon immunotherapy in other thoracic malignancies and uncommon populations. Transl Lung Cancer Res. 2021;10(6):2955\u201369.","journal-title":"Transl Lung Cancer Res"},{"key":"1017_CR73","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1158\/1078-0432.CCR-18-1390","volume":"25","author":"G Lo Russo","year":"2019","unstructured":"Lo Russo G, Moro M, Sommariva M, Cancila V, Boeri M, Centonze G, et al. Antibody-Fc\/FcR interaction on macrophages as a mechanism for hyperprogressive disease in non-small cell lung cancer subsequent to PD-1\/PD-L1 blockade. Clin Cancer Res. 2019;25:989\u201399.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1017_CR74","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1634\/theoncologist.2019-0636","volume":"25","author":"JJ Adashek","year":"2020","unstructured":"Adashek JJ, Kato S, Ferrara R, Lo Russo G, Kurzrock R. Hyperprogression and immune checkpoint inhibitors: hype or progress? Oncologist. 2020;25(2):94\u20138. https:\/\/doi.org\/10.1634\/theoncologist.2019-0636.","journal-title":"Oncologist"},{"key":"1017_CR75","doi-asserted-by":"publisher","first-page":"S338","DOI":"10.1016\/j.jtho.2018.08.276","volume":"13","author":"A Nowak","year":"2018","unstructured":"Nowak A, Kok P, Lesterhuis W, Brown C, Hughes BG, Karikios DJ, John T, et al. OA08.02 DREAM \u2013 A Phase 2 trial of durvalumab with first line chemotherapy in mesothelioma: final result. J Thorac Oncol. 2018;13:S338\u20139.","journal-title":"J Thorac Oncol"},{"key":"1017_CR76","doi-asserted-by":"publisher","first-page":"1088874","DOI":"10.3389\/fimmu.2023.1088874","volume":"14","author":"H Zhou","year":"2023","unstructured":"Zhou H, Luo Q, Wu W, Li N, Yang C, Zou L. Radiomics-guided checkpoint inhibitor immunotherapy for precision medicine in cancer: a review for clinicians. Front Immunol. 2023;14:1088874. https:\/\/doi.org\/10.3389\/fimmu.2023.1088874.","journal-title":"Front Immunol"},{"issue":"16","key":"1017_CR77","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1158\/1078-0432.CCR-20-0020","volume":"26","author":"L Basler","year":"2020","unstructured":"Basler L, Gabry\u015b HS, Hogan SA, et al. Radiomics, tumor volume, and blood biomarkers for early prediction of pseudoprogression in patients with metastatic melanoma treated with immune checkpoint inhibition. Clin Cancer Res. 2020;26(16):4414\u201325. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-0020.","journal-title":"Clin Cancer Res"},{"key":"1017_CR78","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.lungcan.2019.01.010","volume":"129","author":"I Tunali","year":"2019","unstructured":"Tunali I, Gray JE, Qi J, et al. Novel clinical and radiomic predictors of rapid disease progression phenotypes among lung cancer patients treated with immunotherapy: an early report. Lung Cancer. 2019;129:75\u20139. https:\/\/doi.org\/10.1016\/j.lungcan.2019.01.010.","journal-title":"Lung Cancer"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-023-01017-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-023-01017-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-023-01017-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T15:27:56Z","timestamp":1706714876000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-023-01017-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,8]]},"references-count":78,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["1017"],"URL":"https:\/\/doi.org\/10.1007\/s11523-023-01017-w","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"type":"print","value":"1776-2596"},{"type":"electronic","value":"1776-260X"}],"subject":[],"published":{"date-parts":[[2023,12,8]]},"assertion":[{"value":"16 November 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was used in the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Mario Scartozzi declares potential conflict of interests as a member of the speaker bureau and advisory board for MSD, BMS and GSK. Nerina Denaro declares potential conflict as speaker and recipient of honoraria for BMS, Novartis, and MSD. Serafina Martella, Marco Maria Aiello, Valentina Bertaglia, Riccardo Cau, Andrea Cadoni, Silvia Novello, Giuseppe Novello, Hector Jos\u00e8 Soto Parra, Luca Saba, Cinzia Solinas, and Michele Porcu declare that they have no conflicts of interest that might be relevant to the contents of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}}]}}